Executive summary of Chinese expert consensus for topical application of anti-microbial agents for lower respiratory tract infection in adults  

作　　者：Jing Zhang Qijian Cheng Yi Huang Hong Fan Guoxiang Lai Xiangdong Mu Wei Sha Danyang She Ning Shen Xin Su Jinfu Xu Feng Ye Xinlun Tian Tiantuo Zhang Hua Zhou Youning Liu Lixian He Heping Xiao Bei He Yi Shi Xiangyan Zhang Bin Cao Jieming Qu on behalf of Pulmonary Infection Assembly of Chinese Thoracic Society 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,Zhongshan Hospital,Shanghai Medical College,Fudan University,Shanghai 200032,China [2]Department of Pulmonary and Critical Care Medicine,Ruijin Hospital,Institute of Respiratory Diseases,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [3]Department of Pulmonary and Critical Care Medicine,Shanghai Changhai hospital,Navy Medical University,Shanghai 200433,China [4]Department of Pulmonary and Critical Care Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [5]Department of Respiratory and Critical Care Medicine,The Second Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian 350003,China [6]Department of Respiratory and Critical Care Medicine,Beijing Tsinghua Changgung Hospital,Beijing 102218,China [7]Department of Pulmonary Tuberculosis,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [8]Department of Pulmonary and Critical Care Medicine,The First Medical Center of the General Hospital of Chinese People's Liberation Army,Beijing 100853,China [9]Department of Respiratory Medicine,Peking University Third Hospital,Beijing 100191,China [10]Department of Pulmonary and Critical Care Medicine,Nanjing Jinling Hospital,School of Medicine,Nanjing University,Nanjing,Jiangsu 210002,China [11]Department of Respiratory and Critical Care Medicine,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [12]State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou Medical University,Guangzhou,Guangdong 510120,China [13]Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital,Beijing 100032,China [14]Department of Pulmonary and Critical Care Medicine,The Third Affiliated Hospital,Sun Yat-Sen University,Guangzhou,Guangdong 510630,China [

出　　处：《Chinese Medical Journal》2022年第22期2653-2655,共3页中华医学杂志（英文版）

摘　　要：In recent years,with the increased prevalence of multi-drug resistant(MDR)bacterial infection and chronic pulmonary infection,the topical application of anti-microbial agents,mainly inhaled antibiotics,has come back to clinical practice.Several formulations for nebulization and dry powder inhaler(DPI)have been approved for inhaled anti-infective therapy.Meanwhile,evidence and experience have been accumulated in the use of anti-microbial agents delivered via airway.However,the available studies in this field are heterogenous in the study population,drug delivery route and dosages.The efficacy and safety of inhaled anti-infective therapy in various types of lower respiratory tract infections(LRTIs)need to be evaluated.Moreover.

关 键 词：infection DOSAGE application 

分 类 号：R56[医药卫生—呼吸系统]